THE US Food and Drug Administration (FDA) has approved a freeze-dried formulation of the smallpox and mpox vaccine Jynneos.
The live, nonreplicating vaccine is indicated for the prevention of smallpox and mpox, formerly known as monkeypox, in adults 18 years and older, and the current (non-freeze dried) vaccine is the preferred vaccine for use in Australia.
The approval of the freeze-dried formulation improves transport and storage logistics for long-term stockpiling to prepare for outbreaks, without the need for cold chain requirements, as per the current vaccine.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Apr 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Apr 25
